The EMA's CHMP has adopted a positive opinion for Nuedexta (dextromethorphan hydrobromide and quinidine sulphate), from Avanir Pharma, recommending it...
Avanir Pharmaceuticals has submitted an EU marketing authorisation application for Nuedexta (dextromethorphan HBr and quinidine sulfate) for the treatment of...
Avanir Pharmaceuticals announced top-line data from the PRISM II study showing that treatment with Nuedexta (dextromethorphan and quinidine sulphate) was...
Avanir Pharmaceuticals has announced interim data from the Phase IV PRISM II study showing that treatment with Nuedexta (dextromethorphan and...
Avanir Pharmaceuticals announced new findings from the dementia/Alzheimer's disease cohort of the PRISM II study, a Phase IV study evaluating...
Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Avanir Pharmaceuticals, Inc. in which Otsuka America, Inc., a US subsidiary,...